AbbVie (NYSE:ABBV – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.
Analyst Ratings
This is a summary of recent ratings and target prices for AbbVie and CRISPR Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbbVie | 0 | 6 | 22 | 1 | 2.83 |
| CRISPR Therapeutics | 1 | 6 | 8 | 2 | 2.65 |
AbbVie currently has a consensus price target of $297.85, indicating a potential upside of 1.24%. CRISPR Therapeutics has a consensus price target of $72.93, indicating a potential upside of 80.65%. Given CRISPR Therapeutics’ higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than AbbVie.
Risk & Volatility
AbbVie has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.
Institutional and Insider Ownership
70.2% of AbbVie shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares AbbVie and CRISPR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbbVie | 15.67% | -450.55% | 16.50% |
| CRISPR Therapeutics | -1,812.07% | -25.59% | -17.89% |
Earnings & Valuation
This table compares AbbVie and CRISPR Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbbVie | $66.01 billion | 7.88 | $4.23 billion | $5.81 | 50.63 |
| CRISPR Therapeutics | $3.51 million | 1,115.64 | -$581.60 million | ($4.74) | -8.52 |
AbbVie has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Summary
AbbVie beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
About CRISPR Therapeutics
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
